Bride Show Dubai is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Informa
Discover CPHI Frankfurt 2022 on a budget or maximise your networking opportunities in the VIP lounge
Online

28th Sep    12:30 pm

Webinar
Sustainablitity Strategies in the Life Sciences Industries
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.
SPEAKERS
DISCUSSION POINTS
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
TALK SPONSOR

28th Sep

Webinar
Sourcing responsibly - putting ESG principles into practice
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.
SPEAKERS
DISCUSSION POINTS
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
TALK SPONSOR

28th Sep

Webinar
Improving scope 3 emission data quality to drive the decarbonization of our supply chains
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.
In person - day 1

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Sustainability Strategies in the Life Sciences Industry
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.
SPEAKERS
DISCUSSION POINTS
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
TALK SPONSOR

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Sourcing Responsibly – Putting ESG Principles Into Practice
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Why the Pharma Industry Must Address their Carbon Footprint
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.
Set a calendar reminder

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
iGAL 2.0: an Accurate Metric for a Greener Future in Drug Manufacturing – a Supply Chain Perspective
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Sustainability – What Does it Mean for Excipient Makers and Users?
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Sustainable Production of complex API
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.
In person - day 2

3rd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Strategies to Achieve Sustainable Pharmaceutical Manufacturing in LMICs
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.
SPEAKERS
DISCUSSION POINTS
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
TALK SPONSOR

3rd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Strategies to Achieve Sustainable Pharmaceutical Manufacturing in LMICs
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.
An event that works for you

Nothing less than the best results for our exhibitors. Here’s how it happens.

Explore our programe